These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 8607034)

  • 1. Antisense strategies in the treatment of leukemias.
    Calabretta B; Skorski T; Ratajczak MZ; Gewirtz AM
    Semin Oncol; 1996 Feb; 23(1):78-87. PubMed ID: 8607034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oligonucleotide therapeutics: clothing the emperor.
    Gewirtz AM
    Curr Opin Mol Ther; 1999 Jun; 1(3):297-306. PubMed ID: 11713794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multigene targeting with antisense oligodeoxynucleotides: an exploratory study using primary human leukemia cells.
    Opalinska JB; Machalinski B; Ratajczak J; Ratajczak MZ; Gewirtz AM
    Clin Cancer Res; 2005 Jul; 11(13):4948-54. PubMed ID: 16000594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo reversal of multidrug resistance in a human leukemia-resistant cell line by mdr1 antisense oligodeoxynucleotides.
    Cucco C; Calabretta B
    Cancer Res; 1996 Oct; 56(19):4332-7. PubMed ID: 8813118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myb targeted therapeutics for the treatment of human malignancies.
    Gewirtz AM
    Oncogene; 1999 May; 18(19):3056-62. PubMed ID: 10378701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia.
    Ebos JM; Tran J; Master Z; Dumont D; Melo JV; Buchdunger E; Kerbel RS
    Mol Cancer Res; 2002 Dec; 1(2):89-95. PubMed ID: 12496355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antisense strategy in hematological malignancies.
    Warzocha K
    Cytokines Cell Mol Ther; 1999 Mar; 5(1):15-23. PubMed ID: 10390076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antisense strategies for oncogene inactivation.
    Stein CA; Benimetskaya L; Mani S
    Semin Oncol; 2005 Dec; 32(6):563-72. PubMed ID: 16338422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Autologous bone marrow transplantation for patients with chronic myelogenous leukemia after in vitro purging of the graft with bcr/abl antisense oligodeoxynucleotides].
    Sun J; Wu B; Liu Q; Feng R; Liu X; Meng F; Zhou S
    Zhonghua Xue Ye Xue Za Zhi; 2000 Aug; 21(8):400-2. PubMed ID: 11877009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leukemia treatment in severe combined immunodeficiency mice by antisense oligodeoxynucleotides targeting cooperating oncogenes.
    Skorski T; Nieborowska-Skorska M; Campbell K; Iozzo RV; Zon G; Darzynkiewicz Z; Calabretta B
    J Exp Med; 1995 Dec; 182(6):1645-53. PubMed ID: 7500009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo treatment of human leukemia in a scid mouse model with c-myb antisense oligodeoxynucleotides.
    Ratajczak MZ; Kant JA; Luger SM; Hijiya N; Zhang J; Zon G; Gewirtz AM
    Proc Natl Acad Sci U S A; 1992 Dec; 89(24):11823-7. PubMed ID: 1281545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Basics of antisense oligonucleotide therapy and current therapeutical strategies in urology].
    Kausch I; Böhle A
    Aktuelle Urol; 2003 Dec; 34(7):458-68. PubMed ID: 14655082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Antisense oligonucleotides with pharmacologic action].
    Tauşer RG; Stoica O
    Rev Med Chir Soc Med Nat Iasi; 2003; 107(1):40-5. PubMed ID: 14755968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The therapeutic potential of antisense oligonucleotides.
    Sharma HW; Narayanan R
    Bioessays; 1995 Dec; 17(12):1055-63. PubMed ID: 8634067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Bcr-Abl kinase inhibitor INNO-406 induces autophagy and different modes of cell death execution in Bcr-Abl-positive leukemias.
    Kamitsuji Y; Kuroda J; Kimura S; Toyokuni S; Watanabe K; Ashihara E; Tanaka H; Yui Y; Watanabe M; Matsubara H; Mizushima Y; Hiraumi Y; Kawata E; Yoshikawa T; Maekawa T; Nakahata T; Adachi S
    Cell Death Differ; 2008 Nov; 15(11):1712-22. PubMed ID: 18617896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antisense oligonucleotides.
    Calabretta B; Skorski T; Zon G
    Semin Cancer Biol; 1992 Dec; 3(6):391-8. PubMed ID: 1286160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Kinetics of proliferation, differentiation and transcription of genes regulating apoptosis in cultured human BCR/ABL+ Ph+-cells].
    Akhlynina TV; Gerasimova LP; Sarkisian GP; Borovkova TV; Dukhovenskaia EA; Manakova TE; Naĭdenova NM; Timofeev AM; Grineva NI
    Tsitologiia; 2007; 49(10):889-900. PubMed ID: 18074781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prospects for antisense therapy].
    Maekawa T
    Rinsho Ketsueki; 1995 May; 36(5):410-8. PubMed ID: 7783344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perturbing gene expression with oligodeoxynucleotides: research and potential therapeutic applications.
    Gewirtz AM
    Mt Sinai J Med; 1996; 63(5-6):372-80. PubMed ID: 8898543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined transcriptional and translational targeting of EWS/FLI-1 in Ewing's sarcoma.
    Mateo-Lozano S; Gokhale PC; Soldatenkov VA; Dritschilo A; Tirado OM; Notario V
    Clin Cancer Res; 2006 Nov; 12(22):6781-90. PubMed ID: 17121899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.